Status:
COMPLETED
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
Lead Sponsor:
University of Louisville
Collaborating Sponsors:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions:
Multiple Sclerosis, Relapsing-remitting
Multiple Sclerosis, Secondary Progressive
Eligibility:
All Genders
18-55 years
Brief Summary
This study is designed to identify a brief screening evaluation for MS patients that is sensitive and specific to the MS population and which correlates with the findings of our standard-of-care neuro...
Detailed Description
Seventy five randomly identified patients will be evaluated. Consenting patients will perform a Symbol Digit Modalities Test (SDMT) and have the MS Center´s standard neuropsychological assessment perf...
Eligibility Criteria
Inclusion
- EDSS at last visit ≤ 7.0
- Relapsing/Remitting or Secondary Progressive MS
Exclusion
- Severe Depressive Illness: Beck Depression Inventory Score \> 55.
- Unable to read with/without glasses- Visual Acuity better than or equal to 20/60 in one eye.
- Unwilling to sign Informed Consent.
- Evidence on clinical examination of severe dementia at discretion of evaluating neurologist.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00888277
Start Date
May 1 2009
End Date
January 1 2010
Last Update
November 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Louisville
Louisville, Kentucky, United States, 40202